Our Pipeline

Our lead program, VCR-036, is a bi-specific PD-1 + CTLA-4 VINCOBODY designed to deliver the efficacy of combination therapy without the safety trade-offs that limit current regimens.

In preclinical models, VCR-036 has demonstrated:

• Complete tumor regression and durable remission after re-challenge
• Minimal to no immune-related adverse events compared to PD-1 + ipilimumab
• Potent activity at a projected human dose of just 1 mg subcutaneously every six weeks

Beyond VCR-036, our VINCOBODY platform supports rapid expansion into additional immuno-oncology (IO) and antibody drug conjugate (ADC) programs. This includes dual and multi-payload ADC candidates such as VCR-018 (targeting LY75/CD205), designed to overcome limitations in tumor targeting and payload delivery seen with conventional ADCs.